Complex Small Molecules Are Changing Drug R&D

• Structural complexity in modern small molecules is reshaping what drug development partners must deliver from discovery through commercial supply.
• Targeted protein degraders, covalent agents, and a new wave of kinase inhibitors move through pipelines that classical workflows were not built to support.
• When discovery, development, and manufacturing are connected under one partner, decisions made early carry forward—compressing timelines without sacrificing continuity.

SAN DIEGO, CA, June 26, 2026 (GLOBE NEWSWIRE) -- The new small molecules entering R&D pipelines are more structurally demanding. The shift is visible in the molecules themselves. Induced-proximity therapeutics, covalent inhibitors, and newer kinase programs each carry design and process demands that traditional medicinal chemistry hardly handles. Such complexity is changing what a small molecule CRDMO must do to carry a program from discovery to commercial supply. WuXi AppTec, a contract research, development, and manufacturing organization (CRDMO), works as a trusted partner to the biotech and pharmaceutical innovators developing these medicines.

“The field of small molecule drugs is now moving toward a more deliberate discovery paradigm, where advances in screening, structural biology, and systems-level mechanistic and functional analysis are beginning to make the process increasingly predictable and engineerable,” said Dr. Dave Madge, VP, Discovery Services from WuXi AppTec.

What Changed Inside the Molecule

For decades, small-molecule drug discovery focused on finding compounds that could bind disease-relevant proteins with sufficient potency, selectivity, and drug-like properties to produce a therapeutic effect. That foundation remains central today, but the field is now asking small molecules to do more. Targeted protein degraders convert a transient binding event into catalytic removal of a target protein. Covalent agents form a defined bond with a chosen residue, and kinase programs often aim at network effects rather than a single node. Each of these brings questions that classical medicinal chemistry rarely had to answer, from ternary complex formation to linker topology to time-dependent inhibition.

The Success Rate Problem

Today, small-molecule drug discovery is increasingly focused on improving translational success, which requires a new kind of discovery infrastructure. Technologies such as DNA-encoded libraries, fragment-based screening, direct-to-biology platforms, high-resolution mass spectrometry, spatial and cell type-specific analysis, flow chemistry, biocatalysis, and automated reaction optimization are expanding access to new target classes, informing development decisions, and reshaping how complex molecules are synthesized. Their real value, however, depends on integration—bringing together chemical synthesis, structural biology, computational modeling, translational biology, analytical science, and manufacturing into a coordinated system to improve the success rates.

Why Integration Matters

The next frontier in small molecule drug discovery shifts focus from target druggability to target engagement strategy, identifying which approach is most likely to deliver the desired biological outcome and building the workflow to support it. Therefore, drug discovery is evolving from a compound-centric process into an outcome-oriented discipline—one in which success increasingly depends on connecting scientific insight, translational understanding, and development capabilities across the entire discovery continuum.

One System, Start to Finish

When discovery, development, and manufacturing share insights rather than hand a program across organizational walls, decisions can be made several stages ahead, and multiple teams can work on the same project in parallel, shortening the development timeline. More importantly, all the work rests on one global quality system. That continuity accelerates drug development for the clients.

Practical Decisions That Shape Timelines

For teams choosing where to develop and make a complex molecule, the practical decisions arrive early. Process development timelines, target engagement strategy, and whether a single partner can hold a program from the first gram to commercial batch under one quality system all shape how a development path unfolds, often as much as the chemistry itself.

FAQs

Q: What makes complex small molecule discovery different from a traditional one?

A: Newer modalities such as degraders and covalent agents often require unique medicinal chemistry priorities. From molecular weight, polarity, and conformational flexibility to synthetic complexity and analytical performance, we need new strategies to measure, understand, and optimize the properties. That makes reproducibility from laboratory to commercial scale more difficult to achieve, and it rewards process development that starts early rather than after a route is locked.

Q: What should a company look for in a CRDMO for small molecule scale-up?

A: Look for consistent certifications and audit history across all sites, not just chemistry capability. A CRDMO that maintains unified quality standards across its global operations carries process decisions forward without relearning them at each handoff so scale-up doesn't introduce the variability that derails timelines

Q: How early should process development start for a protein degrader or covalent molecule?

A: Earlier than for most conventional small molecules. Degraders and covalent agents carry design complexity that affects route selection, analytical strategy, and scale planning. Addressing those variables before a candidate is fixed reduces the risk of costly rework later in development.

Q: Can one partner cover discovery through commercial manufacturing?

A: An integrated CRDMO is built to do exactly that. Holding a molecule from early discovery through commercial supply under a single quality system means process decisions made in development carry forward without being relearned at each handoff, preserving both continuity and timelines.

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made, and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at https://www.wuxiapptec.com.

Sarah Evans
Head of PR, Zen Media
sarah@zenmedia.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.